Literature DB >> 12753739

Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis.

Shuo Zheng1, Bishnu P De, Suresh Choudhary, Suzy A A Comhair, Tannishia Goggans, Roger Slee, Bryan R G Williams, Joseph Pilewski, S Jaharul Haque, Serpil C Erzurum.   

Abstract

Viral infection is the primary cause of respiratory morbidity in cystic fibrosis (CF) infants. Here, we identify that host factors allow increased virus replication and cytokine production, providing a mechanism for understanding the severity of virus disease in CF. Increased virus is due to lack of nitric oxide synthase 2 (NOS2) and 2', 5' oligoadenylate synthetase (OAS) 1 induction in response to virus or IFNgamma. This can be attributed to impairment of activation of signal transducer and activator of transcription (STAT)1, a fundamental component to antiviral defense. NO donor or NOS2 overexpression provides protection from virus infection in CF, suggesting that NO is sufficient for antiviral host defense in the human airway and is one strategy for antiviral therapy in CF children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12753739     DOI: 10.1016/s1074-7613(03)00114-6

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  49 in total

1.  Lymphocytes in cystic fibrosis lung disease: a tale of two immunities.

Authors:  R B Moss
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

Review 2.  Spectrum of viral infections in patients with cystic fibrosis.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

Review 3.  The airway epithelium: soldier in the fight against respiratory viruses.

Authors:  Marjolaine Vareille; Elisabeth Kieninger; Michael R Edwards; Nicolas Regamey
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 4.  Nitric oxide metabolism in asthma pathophysiology.

Authors:  Sudakshina Ghosh; Serpil C Erzurum
Journal:  Biochim Biophys Acta       Date:  2011-06-21

5.  Differential responses to rhinovirus- and influenza-associated pulmonary exacerbations in patients with cystic fibrosis.

Authors:  Ixsy A Ramirez; Lindsay J Caverly; Lindsay L Caverly; Linda M Kalikin; Adam M Goldsmith; Toby C Lewis; David T Burke; John J LiPuma; Uma S Sajjan; Marc B Hershenson
Journal:  Ann Am Thorac Soc       Date:  2014-05

6.  Eosinophil Peroxidase Catalyzed Protein Carbamylation Participates in Asthma.

Authors:  Zeneng Wang; Joseph A DiDonato; Jennifer Buffa; Suzy A Comhair; Mark A Aronica; Raed A Dweik; Nancy A Lee; James J Lee; Mary Jane Thomassen; Mani Kavuru; Serpil C Erzurum; Stanley L Hazen
Journal:  J Biol Chem       Date:  2016-09-01       Impact factor: 5.157

Review 7.  Host epithelial-viral interactions as cause and cure for asthma.

Authors:  Michael J Holtzman; Dhara A Patel; Yong Zhang; Anand C Patel
Journal:  Curr Opin Immunol       Date:  2011-06-22       Impact factor: 7.486

8.  DNA methylation in lung cells is associated with asthma endotypes and genetic risk.

Authors:  Jessie Nicodemus-Johnson; Rachel A Myers; Noburu J Sakabe; Debora R Sobreira; Douglas K Hogarth; Edward T Naureckas; Anne I Sperling; Julian Solway; Steven R White; Marcelo A Nobrega; Dan L Nicolae; Yoav Gilad; Carole Ober
Journal:  JCI Insight       Date:  2016-12-08

9.  Specific engagement of TLR4 or TLR3 does not lead to IFN-beta-mediated innate signal amplification and STAT1 phosphorylation in resident murine alveolar macrophages.

Authors:  Antonello Punturieri; Rebecca S Alviani; Timothy Polak; Phil Copper; Joanne Sonstein; Jeffrey L Curtis
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

10.  Inflammatory levels of nitric oxide inhibit airway epithelial cell migration by inhibition of the kinase ERK1/2 and activation of hypoxia-inducible factor-1 alpha.

Authors:  Peter F Bove; Milena Hristova; Umadevi V Wesley; Nels Olson; Karen M Lounsbury; Albert van der Vliet
Journal:  J Biol Chem       Date:  2008-04-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.